甲磺酸去铁胺辅助治疗绝经后骨质疏松症的可行性和安全性研究

目的观察甲磺酸去铁胺辅助治疗绝经后骨质疏松的可行性和安全性研究。方法 178例绝经后骨质疏松症女性分为治疗组与对照组,对照组给予雷洛昔芬(60 mg/d)治疗,治疗组在给予雷洛昔芬治疗的基础上添加甲磺酸去铁胺辅助治疗。治疗为期6个月,比较治疗前后两组患者不良反应、骨密度、骨代谢指标的差异和临床疗效。结果截止治疗时间为止,治疗组患者的治疗总有效率为100%,明显高于对照组的84. 27%,差异有统计学意义(P0. 05);两组患者治疗后的腰椎正位、股骨颈骨密度较治疗前均显著上升,且治疗组BMD升高较对照组更为显著,差异均有统计学意义(P0. 05);治疗组的血清骨钙素(OC)、甲状旁腺素(PTH)、血清I型胶原C端肽(CTX-I)、血清铁蛋白水平较治疗前明显改变且改变幅度均明显大于对照组,差异均有统计学意义(P0. 05)。治疗期间两组患者均无明显不良反应发生。结论甲磺酸去铁胺辅助雷洛昔芬治疗能明显提高绝经后骨质疏松患者的骨密度,改善骨代谢指标,且不增加不良反应的基础上增加治疗有效率。

Feasibility and safety of deferoxamine mesylate in the treatment of postmenopausal osteoporosis

Objective To investigate the feasibility and safety of deferoxamine mesylate in the treatment of postmenopausal osteoporosis. Methods A total of 178 cases of postmenopausal osteoporosis were divided into treatment group and control group. Patients in the control group received raloxifene (60mg/day). Patients in the treatment group received deferoxamine mesylate in addition of raloxifene treatment. The treatment was performed for 6 months. The differences of adverse reactions, bone mineral density (BMD), bone metabolic markers, and clinical efficacy between the two groups were compared after the treatment. Results The total efficacy in the treatment group was 100%, which was significantly higher than that in the control group (84.27%), and the difference was statistically significant (P<0.05). The BMD of the lumbar vertebrae and femoral neck in the two groups were significantly higher after treatment than those on the baseline, and the BMD in the treatment group was significantly higher than that in the control group, with statistical significance (P<0.05). Serum osteocalcin (OC), parathyroid hormone (PTH), serum type I collagen C-terminal peptide (CTX-I), and serum ferritin levels in the treatment group were significantly different after the treatment compared with those before treatment, and the changes were significantly smaller than the control group, with statistical significance (P<0.05). There were no significant adverse reactions in both groups during the treatment period. Conclusion Deferoxamine mesylate combined with raloxifene significantly improves BMD and bone metabolism in patients with postmenopausal osteoporosis. The increase in treatment efficiency is not followed by an increase in adverse reaction.